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T-cell receptor (TCR) repertoire data contain information about infections that could be used in
disease diagnostics and vaccine development, but extracting that information remains a major chal-
lenge. Here we developed a statistical framework to detect TCR clone proliferation and contraction
from longitudinal repertoire data. We applied this framework to data from three pairs of identical
twins immunized with the yellow fever vaccine. We identified 500-1500 responding TCRs in each
donor and validated them using three independent assays. While the responding TCRs were mostly
private, albeit with higher overlap between twins, they could be well predicted using a classifier
based on sequence similarity. Our method can also be applied to samples obtained post-infection,
making it suitable for systematic discovery of new infection-specific TCRs in the clinic.
INTRODUCTION
The extremely diverse repertoire of T-cell receptor se-
quences allows the immune system to develop a specific
response to almost any possible pathogen. In recent
years huge progress has been made in the deep profil-
ing of T-cell receptor repertoires by high throughput se-
quencing (HTS), allowing for the identification of mil-
lions of TCR sequences in a single experiment [1]. TCR
sequences and phenotypes and the relative abundances
of the corresponding T-cell clones encode both the his-
tory of previous infections and the protection against
yet unseen pathogens. However, despite recent large-
scale efforts [2, 3], it is still impossible to predict sys-
tematically which antigen is recognized by a TCR with
a given sequence. The most reliable method to iden-
tify antigen-specific TCR — MHC-multimer staining [4]
— is restricted by the choice of HLA alleles (which are
the most polymorphic genes in the human population
[5]), and by the knowledge of immunodominant peptides.
HLA-independent methods for quantitative monitoring
of challenge-specific TCRs in vivo are still lacking.
Here we developed a methodology for identify-
ing responding TCRβ clonotypes from time-dependent
repertoire-sequencing data and applied it to yellow fever
immunization: a classical model of acute viral infection
in humans. The yellow fever vaccine (YFV strain 17D) is
one of the most efficient and safe vaccines ever made [6].
Because YFV 17D is a live attenuated virus, vaccination
leads to viremia and very intense T-cell and humoral re-
sponses [7]. Tracking of activated T-cell subsets such
as CD8+CD38+HLA-DR+ [7] and fluorescent MHC-
tetramer staining [8] make it possible to quantitatively
describe the kinetics of the T-cell response to primary
YFV 17D-immunization. The response peaks around day
14 after immunization, when activated T-cells responding
to vaccination occupy 2-13% of the CD8+ subpopulation
[7–9] and 3-4% of the CD4+ subpopulation [10–12]. Sev-
eral immunodominant peptides were identified and the
corresponding pMHC-multimers have made it possible to
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2track YFV-specific T-cells years and even decades after
immunization [8, 12, 13]. The only repertoire sequenc-
ing study of yellow fever immunization available to our
knowledge [14] reports thousands of CD8+ T-cell clones
expanding after yellow fever immunization, and preferen-
tial recruitment of highly expanded CD8+ T-cell clones
to the memory subpopulation. However, the clonal struc-
ture of the T-cell immune response, how personalized this
response is, and what is the impact of genetic factors on
the response still remain poorly understood. Studying
monozygous twins allows us to quantify the impact of
genetic factors using a small cohort of donors [15–17].
In this study, we identified nearly five thousand YFV
17D-responding T-cell receptors in three pairs of identi-
cal twin donors, using HTS profiling of T-cell repertoires
at different timepoints analyzed with advanced statisti-
cal modeling. We validated the yellow fever specificity
of expanded clones using three independent functional
tests. The detailed analysis of the TCRβ sequences of
the expanded clones showed both a highly personalized
response and high sequence similarity across individuals,
especially between twins. This convergence allowed us
to develop a supervised classifier that predicted YFV-
reactive TCR sequences with high specificity. Remark-
ably, the dynamics of clonal contraction in the month
after the peak response specifically predicts the YFV-
reactive clonotypes. Thus, our methodology can be used
during the post-infection period in the clinic to identify
TCR clonotypes that recognized and responded to an
acute infection of interest, even without prior knowledge
of donor MHC-alleles or pathogen epitopes.
RESULTS
Detection of significantly expanded TCRβ following
YFV 17D-vaccination
Blood samples were obtained for three pairs of iden-
tical twin volunteers aged 20-23. We collected periph-
eral blood samples on 5 different timepoints (2 before
and 3 after immunization) with the live attenuated YFV-
17D vaccine (see Fig. 1A). On each timepoint, we col-
lected two biological replicates — two independent tubes
of blood — to isolate bulk PBMC, and another tube of
blood to isolate CD4+ and CD8+ T-cell subpopulations.
Additional portions of blood were used for other subpop-
ulations isolation (CD45RO+) and functional tests on
several timepoints (see Methods for details). From each
sample, cDNA libraries of TCRβ chains were prepared as
previously described [18], and sequenced on the Illumina
HiSeq platform.
We developed a Bayesian statistical framework that
identifies T-cell clonotypes both significantly (p < 0.05)
and strongly (fold change > 32) expanded between dif-
ferent timepoints compared to the expected variability
between replicates (see Methods). We reproduced the re-
sults with the edgeR package [19]: a widely used method
to analyze differential gene expression in RNAseq exper-
iments (see Methods). In Fig 1B we show the number
of clonotypes identified as expanded with respect to day
0. In all donors we observe many more expanded clono-
types between day 0 and day 15 than for any other pair
of timepoints, despite variations between donors. In the
following we simply call expanded clonotypes TCRβ se-
quences that significantly increased in fraction between
days 0 and 15. Clonotypes with a significantly higher fre-
quency on the pre-vaccination timepoint relative to the
vaccination timepoint (day 0 vs day -7, so actually cor-
responding to a contraction) were relatively few for all
donors except for P1, who we speculate was undergoing
another transient immune response.
Most expanded clones were not detected before immu-
nization, and often not even on day 7, due to their low
frequency. We report expansion rates of up to 2000-3000
fold in 7 days, although this estimate is only a lower
bound due to lack of detection prior to day 15 (see SI
Fig. S4).
The majority of expanded TCRβ are YFV
17D-specific
We hypothesized that most of the expanded clonotypes
proliferated specifically in response to the YFV-17D vac-
cine. To check this hypothesis, three independent func-
tional tests with subsequent TCRβ repertoire sequencing
were performed on donor S1: (i) interferon (IFN) gamma
secretion assay; (ii) fluorescent sorting of the activated
CD8+CD38+HLA-DR+ subset, which was reported to
be largely YFV 17D-specific at the peak of the response
[7]; (iii) staining with a MHC-dextramer loaded with
an immunodominant epitope. For (i), whole blood was
incubated with the YFV-17D vaccine and IFN-gamma
producing cells were isolated using magnetic beads (see
Methods). For (i) and (ii), we considered the clonotype
validated if it was enriched in the IFN-gamma positive (i)
or CD8+CD38+HLA-DR+ (ii) fractions, by comparison
to the bulk PBMC or CD8+ populations respectively.
Enrichment was determined by a one-sided exact Fisher
test (see Methods). We found that out of 774 clonotypes
expanded in donor S1 (see Fig 1B.), 331 were enriched
in the CD8+CD38+HLA-DR+ fraction (see Fig. 1C),
and 64 were enriched in the IFN-gamma secretion as-
say. For (iii) we used the HLA-A*02 dextramer loaded
with the immunodominant YFV epitope NS4b214−222
(LLWNGPMAV) on a sample collected 2 years after im-
munization. Dextramer-positive cells were isolated and
the TCRβ repertoire was sequenced. We found 68 ex-
panded clonotypes in the A02-NS4b214−222 dextramer
positive fraction. We used this data to estimate the frac-
tion of response to the immunodominant epitope A02-
NS4b214−222 in this donor. We found that at least 22%
of the CD8+ response to YFV vaccination (identified by
our statistical model) consisted of NS4b214−222-specific
clonotypes on day 15 after immunization. We also se-
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FIG. 1. A. Yellow fever vaccination study design. Top: the experimental timeline with the list of samples collected at each
timepoint. Unsorted PBMC samples were collected in two biological replicates at each timepoint. Bottom: method overview.
Peripheral blood samples were subjected to PBMC isolation, synthesis of TCRβ cDNA libraries, Illumina sequencing, and
reconstruction of TCRβ repertoires. B. The number of significantly expanded clonotypes in comparison to day 0. The
number peaks at day 15 for all donors. The comparison to day -7 corresponds to a contraction reflecting the normal dynamics
of a healthy repertoire in absence of vaccination. C. Activated CD8+CD38+HLA-DR+ subpopulation is enriched
with clonotypes expanded between days 0 and 15. The relative abundance of a clonotype in the CD8+CD38+HLA-
DR+ activated subpopulation (x-axis) is plotted against the relative abundance in the bulk CD8+ population isolated at the
same timepoint (y-axis). Yellow dots indicate clonotypes that strongly expanded between day 0 and day 15. Black line shows
identity. Red circles indicate that the clonotype was found in the A02-NS4b214−222-dextramer-positive fraction 2 years later.
quenced unsorted PBMC for the 2 year timepoint of this
donor and found that the fraction of the repertoire oc-
cupied by the yellow fever responding clones largely de-
clined 2 years after immunization: from 2.1% (on day
45) to 0.07%, but still exceeded prevaccination levels by
nearly two orders of magnitude.
Overall, the total number of clonotypes validated by
any of the three methods was 395 out of 774. Notably,
the remaining unvalidated clonotypes had significantly
lower average frequencies than the validated ones on day
15 (t-test p-value< 10−16, SI Fig. S5). We performed
a randomization control to check the specificity of our
validation approach: 774 clonotypes were randomly sub-
sampled from the repertoire on day 15, with the proba-
bility of being sampled taken to be proportional to the
clonotype frequency. We then tested this random subset
for enrichment in the same way we did for the expanded
clonotypes. On average, over 1000 such randomizations,
we found 29.2(±0.15) random clonotypes enriched in the
CD8+CD38+HLA-DR+ subset (compared to 331 in the
actual expanded clones), 8.3(±0.1) clonotypes enriched
in the IFN-gamma fraction (vs. 64 among expanded
clones) and 6.4(±0.1) clonotypes enriched in the A02-
NS4b214−222 dextramer positive fraction (vs. 68 among
expanded clones). Note that this control gives a con-
servative estimate of validation specificity, because the
expanded clones (true positives) are still likely to be sam-
pled in this randomization due to their high frequency on
day 15.
To further validate the expanded clones for YFV-
17D specificity, we used previously published TCRβ se-
quences from the VDJdb database [20] (https://vdjdb.
cdr3.net, see SI data) that lists sequences specific for
the the NS4b214−222 YFV-17D immunodominant epi-
tope. We checked if these published TCRβ sequences
were present in our donors, and whether they were
expanded after vaccination. We screened the CD8+
TCRβ repertoires of our donors at different timepoints
for A02-NS4b214−222 specific sequences, as well as for se-
quences specific for an unrelated epitope as a control: the
cytomegalovirus (CMV) immunodominant HLA-A*02-
restricted pp65495−503 peptide (NLVPMVATV). All of
our donors are HLA-A*02-positive (complete HLA geno-
types can be found in SI Table S1). We found that both
the number of hits and their cumulative frequency (SI
Fig. S1) were significantly higher for published A02-
NS4b214−222-specific sequences on day 15 than on day 0
(one-sided t-test p=0.019). By contrast, in the control no
significant difference was found (one-sided t-test p=0.27).
Then we checked if published A02-NS4b214−222-specific
sequences could be found in sets of expanded clonotypes
identified in each donor by our model (SI Table S2).
We found multiple exact matches for published A02-
NS4b214−222-specific sequences and no exact matches for
CMV-specific A02-pp65495−503 clonotypes.
In summary, the expanded clonotypes were validated
for their YFV specificity, and were also consistent with
published YFV-specific TCRs.
The CD8+ T-cell response is sustained longer than
the CD4+ response
To track the fractions of the CD4+ and CD8+ reper-
toires involved in the response over time, we calcu-
lated the cumulative frequency of expanded clonotypes
in the CD4+ and CD8+ compartments at each time-
point. We found similar dynamics in all donors, with
both CD8+ and CD4+ responses peaking on day 15. In
all donors the CD4+ response fell off more quickly than
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FIG. 2. Dynamics of YFV-specific T-cells in the CD4+
and CD8+ compartments. The total fraction of (A)
CD4+ and (B) CD8+ repertoires occupied by clonotypes sig-
nificantly expanded from day 0 to day 15 for different time-
points. CD4+ and CD8+ T-cell subpopulations show similar
dynamics, although the CD8+ response degrades more slowly.
Error bars are smaller than one line width. Panels C. and D.
show the same data on a logarithmic scale.
the CD8+ response from day 15 to day 45, with a mean
12.8(±3) fold decrease for CD4+, versus 5.4(±1.4) for
CD8+ (p = 0.023, paired one-sided t-test). We checked
the significance of this difference in decay for each donor
separately using our statistical framework (see Methods).
Briefly, for each clonotype we redrew a random number of
counts on days 15 and 45, with the same variability as in-
ferred from replicate experiments to mimic experimental
noise. Repeating this process many times gave a p-value
corresponding to the fraction of numerical experiments
where the ordering between CD4+ and CD8+ decay was
opposite to the actual observation. CD4+ and CD8+ fold
decreases significantly differed (p < 0.0001) for 5 donors
out of 6, with the exception of donor Q1 (p = 0.15) who
was an outlier in the CD8+ response strength and the
number of significantly expanded clones. The respond-
ing clonotypes at the peak of the response occupied up
to 8% of the repertoire (cumulative frequency) for CD8+
and up to 5% for CD4+ T-cells. Almost all these clono-
types were undetected before immunization.
The previous analysis described the dynamics of the
CD4+ and CD8+ responses separately. What is the rela-
tive importance and diversity of the CD4+ and CD8+ re-
sponses within the overall T-cell population? To answer
this question, we associated expanded clonotypes from
the unsorted PBMC sample to either the CD4+ or CD8+
subsets in the following way: we labeled an expanded
TCRβ clonotype from the unsorted PBMC sample CD4+
if it had a larger concentration in the CD4+ subpopula-
tion sequenced than in the CD8+ subpopulation, and
vice versa. This procedure gave unambiguous in silico
phenotypes for each expanded clonotype sequence from
the PBMC at day 15: the relative abundance of sequences
in the CD4+ versus CD8+ compartments was strongly
bimodal, with two peaks close to 100% CD4+ and 100%
CD8+ (see SI Fig. S2). This analysis revealed that both
CD4+ and CD8+ clones strongly expanded in response
to the vaccination, with no strong preference for CD4+
or CD8+ expanded clonotypes in terms of the cumulative
frequency or diversity (see SI Fig. S3). We next asked
if the presence of expanded clonotypes in the memory
(CD45RO+) compartment 45 days after immunization
depends on their CD4+ or CD8+ phenotype. We de-
tected on average 49% (±7 %) of CD4+ expanded clono-
types in memory repertoires 45 days after immunization,
versus only 21% (±3 %) of CD8+ expanded clonotypes.
This may be explained by different levels of CD45RO+
expression in CD4+ and CD8+ memory T-cells reactive
to yellow fever.
TCR response is highly personalized even among
twins
Our method not only reconstructs the dynamics of im-
mune response, but also enables the analysis of TCR
sequences of the responding T-cell clones. For each
donor we found 500-1500 YFV-17D reactive clonotypes
expanded between day 0 and day 15. We compared
the pairwise sharing of responding amino acid TCRβ se-
quences between different individuals. We found more
overlap in twins than in non-related individuals (see Fig.
3A). However absolute numbers of identical expanded
TCRβ clonotypes were low even in twin pairs (up to 20
out of 1503 amino acid sequences), indicating that each
individual developed an almost unique response. We also
observed that the same nucleotide variants encoded some
of the amino acid TCRβ sequences shared between the
twins (see SI Table S4). This identity of nucleotide vari-
ants was more frequent in twins than expected from con-
vergent recombination alone (p < 0.021, see Methods).
Overall, shared clonotypes (across at least two donors)
accounted for a small fraction of the response in each
donor. Only 2.5%-4.4% of unique responding TCRβ se-
quences were public (present in more than one donor).
These clonotypes correspond to 2.7%-34% of YF-specific
cells (see SI Table S3). Despite the low numbers of
shared clonotypes, normalized sharing of YFV-17D re-
active amino acid clonotype sequences was more than
two orders of magnitude higher than in the total reper-
toire both for twins and unrelated individuals (Fig. 3B).
This may result from convergent selection of the same
TCR variants recognizing the same epitopes in different
donors.
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FIG. 3. The normalized number of identical yellow fever vaccine (YFV-17D) specific TCRβ amino acid sequences
between different donor pairs. (A) The heatmap shows the number of the identical TCRβ clonotypes between two sets
of clones significantly expanded from day 0 to day 15, divided by the product of sizes of these sets. All twin pairs show higher
numbers of identical expanded clonotypes than unrelated individuals and are clustered together by hierarchical clustering
(dendrogram on top). (B) The normalized sharing of YFV 17D-specific TCRβ clonotypes (left) is much higher than the
normalized sharing in the whole repertoire (right). Sharing in twins (red circles) exceeds sharing in unrelated individuals (dark
blue circles) in all cases.
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FIG. 4. Convergence of amino acid sequences inside the YFV-reactive TCR repertoire. (A) The number of pairs
of similar clones (exact same CDR3 amino acid sequence - left panel, up to 1 mismatch - middle panel, up to 2 mismatches
- right panel) normalized by the number of possible pairings in each individual (see Methods). The number of similar clones
in the data (yellow dots) is larger than the number of similar clones in randomly drawn samples (dark blue dots) of the same
size (one sided paired t-test, p = 0.022, 0.015, 0.008 for 0 , 1, and 2 mismatches respectively). As a reference, the red dots
show an example of a restricted and specific repertoire for the yellow fever virus immunodominant epitope NS4b214−222 (data
from VDJdb [20], see SI data). (B) 1000 most abundant TCRs from donor S1 at day 15. Each vertex corresponds to a TCRβ
amino acid sequence; edges connect clonotypes differing by 2 or fewer amino acids in their CDR3. Yellow clonotypes indicate
expanded TCRs, while blue clonotypes were present before immunization at similar frequencies as on day 15. The vast majority
of edges (95 out of 103) are formed between TCRs of the same status (expanded or not expanded).
TCR sequence analysis reveals a mixture of
convergent and private response
It was previously shown that in many cases TCRs rec-
ognizing the same antigens have restricted sequence di-
versity [2, 21]. To analyze the sequence diversity of re-
sponding TCRs, we performed a pairwise comparison of
all expanded TCRβ sequences within each donor at the
amino-acid level. In each individual, we identified many
more pairs of expanded TCRs with the same or highly
6similar CDR3β amino acid sequences (up to 0, 1, or 2 aa
mismatch) on day 15 than in a random subset of equal
size (see Fig. 4A). Interestingly, our expanded TCRs
were still more diverse than published TCRs selected for
their specificity to a single immunodominant YFV epi-
tope NS4b214−222 (red dots, data from VDJdb [20], see
SI data), suggesting that the response is directed against
multiple epitopes in each donor. Consistent with the idea
of multiple specificities, the expanded TCRs form mul-
tiple dense clusters of highly similar clones (Fig. 4B,
yellow circles). By contrast, pre-vaccination abundant
TCRs form fewer, sparser, and smaller clusters (blue cir-
cles).
Sequence score based on distance to expanded TCR
predicts YFV-17D specificity
The similarity of sequences in the expanded repertoire
makes it possible to build a simple classifier to identify
novel YFV 17D-specific clonotypes. For each TCR of
interest we defined a YFV specificity score as the Ham-
ming distance to the closest amino acid sequence neigh-
bour among the expanded clonotypes from all 6 donors.
To test how informative this score is about YF speci-
ficity, we first applied it to published TCRs (from VDJdb
[20], SI data) specific to the NS4b214−222 epitope from
YFV-17D and to the pp65495−503 epitope from CMV as
a negative control. We found that published YF-specific
clonotypes were much closer to our set of expanded clones
than CMV-specific clonotypes (Fig. 5A), with some ex-
act matches for YF-specific but none for CMV-specific
sequences (SI Table S2). Accordingly, using the score to
discriminate YF-specific from CMV-specific published se-
quences yields good specificity and sensitivity (Fig. 5B).
We then asked if the score could be used to identify re-
active clonotypes in the repertoire of an individual after
immunization. To test this capability, we used a leave-
one-out approach. Information about expanded clono-
types in five individuals was used to build a score as
described earlier. The score was then used to predict ex-
panded clonotypes among the 1000 most abundant ones
at day 15 in the sixth individual. The score performed
with similar accuracy as on published epitope-specific
clonotypes (Fig. 5C).
Retrospective detection of YFV 17D-reactive TCRs
using post-vaccination data
So far we have identified responding TCRs as those
that significantly expanded between days 0 and 15.
While pre-challenge timepoints are easy to collect in vac-
cination studies, this is not the case for acute infections,
where the first samples can usually be obtained only af-
ter the onset of symptoms, when it is too late to detect
TCR expansion. However, the clonal contraction dynam-
ics (Fig. 2, day 15 to day 45) can in principle be used
to identify responding clonotypes, by comparing a time-
point taken on the peak of the response to a timepoint
taken several weeks or months after the infection.
To demonstrate the feasibility of this detection on our
data, we identified significantly (p < 0.05, fold change
> 1, see Methods) contracted clonotypes between day
15 and day 45 using our model. We computed the over-
lap between this set of candidate TCRβ clonotypes with
the subset of expanded clonotypes obtained before (Fig.
6). Strikingly, 73% to 97% of the significantly contracted
TCRs were also present in the expanded subset, showing
that the contraction dynamics can help to identify YFV-
reactive clonotypes with high specificity. This method is
also sensitive: 47% to 80% of expanded TCRs could be
identified by contraction. This shows that contraction
dynamics alone is sufficient to identify a large fraction
of the responding TCRs. Thus, our method could be
used to identify clonotypes responding to infections in
the clinic, when pre-infection timepoints are not avail-
able.
DISCUSSION
In this study we used high-throughput TCRβ reper-
toire profiling to identify major changes occurring in the
repertoire after immunization with the live attenuated
YFV-17D vaccine. We found several hundreds of unique
TCR clones in each donor expanded in response to vac-
cination. A strong clonal expansion of up to > 2000 fold
occurred between days 7 and 15 following vaccination.
This proliferation corresponds to at least 11 divisions in
7 days, with an average of 15 hours per cell cycle. Simi-
lar division rates (doubling times of 8-15 and 11-17 hours
for CD4+ and CD8+ T-cells respectively) were observed
for LCMV infection [22] and also in adoptive transfer
experiments in mice (18 hours) [23]. However, in our
case the actual expansion rate could be much higher, be-
cause when a clonotype is not found on day 7, its initial
concentration is unknown, providing only a lower bound
estimate of the fold change. Higher sequencing depth or
shorter intervals between timepoints are needed to refine
this estimate of expansion rates. This extension would
allow us to study the impact of the T-cell clone phe-
notype and the TCR sequence on the clonal expansion
rate. Initial low concentrations of YFV-reactive clono-
types suggest their naive phenotype.
Our longitudinal approach can be applied to iden-
tify antigen-specific clonotypes for poorly characterized
pathogens with unknown epitopes, which may be useful
to study the immune response to emerging viral infec-
tions. One could also use this approach to track the
response to infection and vaccination of unconventional
T-cell subsets for which antigens are still unknown (i.e.
γδ T-cells).
While analysing expansion between a pre-vaccination
timepoint and the peak of the T-cell response (day 15
in our case) is the the most natural choice, for real-
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specific sequences using the minimal distance to the expanded TCRs identified in this study. (C) ROC curves for “leave-one-out”
classifier validation. The top 1000 most abundant TCRs of each individual were classified as YFV-reactive or non YFV-reactive
according to their minimal distance to TCRs expanded in the other five individuals.
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FIG. 6. Clonal contraction can be used to identify
YFV-17D reactive clonotypes with high specificity
and good sensitivity. Venn diagrams show overlap between
the subset of TCR clones significantly expanded from day 0 to
day 15 (red), and the subset of TCR clones significantly con-
tracted from day 15 to day 45 (blue). All donors show large
overlaps between the contracting and expanding subsets.
world, non-experimental acute infections, acquiring a
pre-infection time point is often impossible or imprac-
tical. In this case, we showed how to use the dynamics
of clonal contraction to identify reactive clonotypes, by
comparing their abundance at the peak of the response
to a timepoint taken a few weeks later. Implementing
such a protocol in the clinic would lead to an exponen-
tial growth of the number of annotated TCR sequences
specific to a range of infectious diseases, facilitating di-
agnostics and vaccine design.
Simultaneous sequencing of bulk PBMC, CD4+ and
CD8+ subsets allowed us to determine the phenotype
of the responding clones and to describe the kinetics of
the response inside each compartment. While Blom et al.
[10] found that YFV-specific CD4+ T-cells concentration
peaked slightly earlier than CD8+ T-cells, we did not
detect any difference in the expansion kinetics with our
limited temporal resolution. More timepoints between
days 7 and 15 could have been helped to detect such dif-
ferences. However, we did find differences in the contrac-
tion kinetics, with CD4+ cells contracting faster than
CD8+ cells. We also found differential recruitment to
the CD45RO+ memory compartment, with many more
CD4+ than CD8+ TCRs detected in the CD45RO+ frac-
tion on day 45. CD8+ memory formed in response to
YFV-immunization was shown to be largely CD45RA+
[8, 10, 13], whereas James et al. [24] found that CD4+
memory cells were mainly CD45RA-. Our results sug-
gest that CD4+ and CD8+ YFV-reactive memory pop-
ulations also differ in their CD45RO expression.
To the best of our knowledge, our study is the first to
describe the reaction of the T-cell repertoire in a model
of an acute infection in genetically identical individuals.
It was previously shown that the T-cell repertoires of
8twins have more sequence overlap in abundant clono-
types [15, 16]. Part of this extensive overlap may be
explained by in utero sharing of T-cells [18]. Authors
in [17] also found more overlap in vaccinia virus-specific
CD4+ repertoires (isolated by in vitro cultivation with
the antigen) in twins. Consistent with these findings, we
report more TCRβ amino acid sequence overlap in the
YFV-reactive repertoires of twins than in those of unre-
lated individuals. Twin YFV-specific TCRβ clonotypes
also show higher nucleotide sequence overlap than those
of unrelated individuals, even relative to their higher
amino acid sequence overlap (see SI Table S4). To as-
sess the significance of this observation, we used a gen-
erative model to ask how likely it is to produce such an
amount of shared nucleotide sequences by convergent re-
combination (see Methods). In the vast majority of sim-
ulations (p < 0.021) the model underestimates the num-
ber of shared sequences between twin donors. We specu-
late that some of these shared TCRs were exchanged in
utero. Yet two thirds of YF-reactive TCRβ amino acid
sequences shared between twins have different nucleotide
sequences and can only be explained by convergent re-
combination and selection. Our results also suggest a
mechanism for the previously reported extensive sharing
of abundant TCRs in twins [15]. Under this mechanism,
twins would share more TCR sequences expanded in re-
sponse to the same infection.
We showed that the response to the vaccine is very di-
verse, with few TCRs shared even between donors with
identical genetic and environmental backgrounds. Nev-
ertheless, using a simple similarity measure, it is possi-
ble to identify YFV-specific clonotypes from yet unseen
repertoires with high specificity, using datasets of TCRs
with known YFV specificity. The sensitivity of this clas-
sifier could be improved by collecting more examples of
YFV-specific TCRs from more donors. We also show
how published antigen-specific sequences can be used for
functional repertoire annotation. On day 15 after immu-
nization we found a much higher cumulative frequency of
published A02-NS4b214−222-specific sequences compared
to pre-vaccination levels. Yet only a few significantly ex-
panded clones matched those published sequences. This
could be explained in two possible ways. First, our signif-
icantly expanded clones may be specific to epitopes other
than NS4b214−222. Second, the A02-NS4b214−222 specific
T-cell repertoire may be so diverse that little overlap is to
be expected between random subsamples of it. Further
accumulation of antigen-specific TCR sequence data —
acquired by sequencing of multimer-specific cells, longi-
tudinal studies as done here, and from disease-associated
studies with large cohorts [25–27] — will provide the
means for disease diagnostics and extraction of clinically
relevant information from T-cell repertoire data.
MATERIALS AND METHODS
Blood donors and samples
Three pairs of healthy monozygous twins participated
in this study. Monozygosity was confirmed using poly-
morphic Alu-insertion genotyping [28]. All donors were
HLA-typed using an in-house HTS-based solution (see
Table S1). None of the participants have ever been vac-
cinated with YFV-vaccine or traveled to Africa or South
America. The blood was collected with informed consent
in a certified diagnostics laboratory. For each unsorted
PBMC sample we used 4 ml of whole blood per biological
replicate, and another 4 ml for CD4+ and CD8+ subpop-
ulation isolation using Dynabeads CD4+ and CD8+ pos-
itive selection kits (Invitrogen), and 4 ml for CD45RO+
subpopulation isolation using the CD45RO+ positive iso-
lation kit (Miltenyi Biotec). PBMC were isolated with
the Ficoll-Paque method according to the manufacturer’s
protocol. All isolated cells were immediately lysed with
the Trizol reagent (Invitrogen).
MHC-dextramer staining
Staining with HLA-A*02 the dextramer loaded with
the NS4b214−222 peptide (LLWNGPMAV) from YFV-
17D (Immudex) was performed according to the man-
ufacturer’s protocol. 25 ml of whole blood was used
for PBMC isolation using the Ficoll protocol, PBMCs
were stained with MHC-dextramer-PE, and also anti-
CD8-FITC (Beckman Coulter, dilution 1:100) and anti-
CD3-PC5 antibodies (eBioscience, dilution 1:100).
HLA-DR staining
Isolated PBMCs were stained with anti-CD8-FITC
(Invitrogen, dilution 1:100), anti-CD38-PE (eBioScience,
dilution 1:100), anti-HLA-DR-PerCP (Invitrogen dilu-
tion, 1:100) according to the manufacturer’s instructions.
IFN-gamma secretion assay
The IFN-gamma secretion assay was performed using
the IFN-gamma Secretion Assay - Cell Enrichment and
Detection Kit (PE human, Myltenyi Biotec). 2.5 ml of
whole blood was incubated with 104/ml YFV-17D parti-
cles and 5 ug/ml of the anti-CD28 antibody (eBioscience)
for 5 hours. The same amount of blood was incubated
with the same amount of media without virus particles
and with 5 ug/ml of the anti-CD28 antibody and used
as negative control. After stimulation erythrocytes were
lysed with ACK Lysing Buffer (Gibco, Thermo Fisher
Scientific), and white blood cells were washed by PBS.
The secretion assay and IFN-gamma positive cells iso-
lation were performed according to the manufacturer’s
9protocol using MACS LS Columns (Myltenyi Biotec).
anti-CD8-P5 (Beckman Coulter, dilution 1:100) and anti-
CD3-FITC (eBioscience, dilution 1:100) antibodies were
added along with the IFN-gamma detection antibody at
the corresponding step. Aliquot (1/10) of isolated cells
were analyzed by FACS and all other cells were lysed in
500 ul of Trizol reagent (Invitrogen) and used for subse-
quent RNA isolation.
Analysis of sequencing data of functional assays
All three functional assays (IFN-gamma secre-
tion assay, CD8+CD38+HLA-DR+ staining and A02-
NS4b214−222 dextramer staining) provided us with TCRβ
repertoire sequencing information. However, both flu-
orescence activated cell sorting after dextramer stain-
ing, activation marker staining and magnetic column
enrichment are not completely precise. These meth-
ods enrich resulting samples with YF-specific cells, but
abundant irrelevant cells are still found in the corre-
sponding repertoires. To detect clonotypes enriched
in the CD8+CD38+HLA-DR+ population, the IFN-
gamma producers population or the tetramer-positive
population in comparison to the bulk population at the
same timepoint we used Fisher’s exact test, as suggested
in Ref. [14]. For each clone the number of barcodes oc-
cupied by it in the activated population, the number of
barcodes occupied by other clonotypes in the activated
population, the number of barcodes occupied by the clone
in the bulk population and the number of barcodes oc-
cupied by all other clones in the bulk population formed
a 2× 2 contingency table, and then one way Fisher’s ex-
act test was applied. This procedure was repeated for
each clone found in the activated population, clones with
BH-corrected p-values<0.05 were considered significantly
enriched in the activated population.
TCRβ cDNA library preparation and sequencing
TCRβ cDNA library preparation was performed as de-
scribed in Ref. [18]. Briefly, PBMC were isolated from
whole blood using the Ficoll density gradient, the to-
tal RNA was isolated using the Trizol reagent (Invit-
rogen). cDNA synthesis with template switch was fol-
lowed by two steps of PCR amplification to introduce
adapter sequences necessary for sequencing on the Illu-
mina platform. Unique molecular identifiers (UMI) were
introduced into each cDNA molecule using the template
switch effect on the cDNA synthesis step. This allowed
us to know the number of cDNA molecules corresponding
to each clone, instead of number of raw sequencing reads
and thus to correct for PCR bias.
Samples were sequenced on the Illumina HiSeq 2500
with 2×100 read length. Samples from twin donors were
processed and sequenced separately, to prevent contam-
ination and sample barcode exchange on Illumina flow
cell.
Raw data analysis
Raw data was demultiplexed and clustered by UMI
using the MIGEC software [29], alignment of V,D,J tem-
plates was then performed by MiXCR [30].
Statistical analysis
Candidate responding clones were identified using a
model of mRNA count statistics accounting for differ-
ential expression and the sequencing process [Puelma
Touzel et al, in preparation]. The normalized clone
size, f , is distributed according to the probability den-
sity function ρ(f), bounded by M−1T ≤ f ≤ 1, where
MT = 10
11 is an estimate of the total number of lympho-
cytes in an individual. Based on previous observations
[31–33], ρ(f) is set as a power-law, i.e. ρ(f) ∝ f−γ .
A clone of size f appears in a sample containing M
lymphocytes on average as fM cells. To account for
overdispersed count statistics, the number of cells is set
to be Negative-Binomial distributed with mean fM and
variance fM + a(fM)β , with a > 0 the coefficient and
β > 1 the power controlling the over-dispersion. For each
clone, the number n of detected mRNA molecules (i.e.
UMI) is distributed according to a Poisson distribution
with mean mN/M , where N/M is the average number of
UMI per cell, obtained using the observed total number
of molecules, N .
We inferred the parameters of this model, θ =
(γ,M, a, β), from day-0 replicates by maximizing the like-
lihood of the observed count pairs, (n1, n2), where ni ∼
Poisson(miNi/M), mi ∼ NegBin(fM, fM + a(fM)β),
for each replicate i = 1, 2, and f ∼ ρ is common to both
replicates. For a given pair, the likelihood, P (n1, n2|θ),
is obtained by marginalizing over m1,m2, and f .
We introduce a selection factor s defined as the log-
fold change between a clone’s frequency on one day, f ,
and that on another, fes, and define P (n1, n2|s, θ) as
before, but replacing f by fes in the definition of m2.
Given a prior distribution P (s|θ′) over s parametrized
by a set of parameters θ′ distinct from θ, we used Bayes
rule to obtain the posterior log fold-change probability
function given an observed count pair, P (s|n1, n2, θ, θ′).
In analogy with p-values, we used the posterior prob-
ability corresponding to the null hypothesis that they
are not expanded, p = P (s ≤ 0|n1, n2, θ, θ′) to rank
the clones by the significance of their expansion, us-
ing a threshold of p < 0.025. We parametrize our
prior as P (s|θ′) = (α/2s¯) exp(−|s|/s¯) + (1−α)δ(s), with
0 ≤ α ≤ 1 the fraction of clones that respond to the
change, and s¯ > 0 their typical effect size. We set the
values of the parameters θ′ = (α, s¯) of this prior by again
maximizing the likelihood of the count pair data given
the model over θ′,
∫
P (n1, n2|s, θ)P (s|θ′)ds.
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Identification of expanded clones using edgeR
To check robustness of our clonal expansion model we
also used an independent approach to detect expanded
clones. edgeR [19] is a package used to analyse a vari-
ety of count data produced with HTS. It was applied for
differential gene expression analysis, differential splicing
analysis and bisulfite sequencing. Here we apply statis-
tical tests implemented in the edgeR package to iden-
tify clones expanded after YFV immunization. Two bi-
ological replicates were used for each timepoint, TMM-
normalization and trended dispersion estimates was per-
formed as described in the edgeR manual. An exact
test based on the quantile-adjusted conditional maximum
likelihood (qCML) was used to identify clones signifi-
cantly expanded between pairs of timepoints. A clono-
type was considered significantly expanded, if it’s log2
fold change estimate log2FC>5 and it’s p-value after mul-
tiple testing correction was lower than 0.01. We repro-
duced the main results described in the manuscript text
using clonotypes identified as significant by edgeR (see
SI Fig. S6), so two differential clone expansion models
agree with each other.
Sequence similarity analysis
We used the Hamming distance to quantify CDR3 se-
quence similarity in each YFV-reactive repertoire. We
counted the number of CDR3 amino acid sequence pairs,
which are 0 mismatches (same amino acid, but differ-
ent nucleotide sequences), 1 mismatch or less, 2 mis-
matches or less from each other. Since the number of
YFV-reactive clones varied among donors, the number of
similar clones inside each YFV-reactive repertoire needed
to be normalized. We divided it by n(n− 1)/2, which is
the total number of possible clone pairs. We randomly
sampled clonotypes from the same timepoint for com-
parison, and found a smaller number of similar pairs. In
Fig. 4A. we plot the normalized sharing in log scale to
compare these values.
Nucleotide sequence sharing analysis of
YFV-reactive clonotypes
To see, if the excess of nucleotide sequence sharing
in twins may be explained by convergent recombination,
we performed the following simulation: for each donor,
for each shared YFV-specific TCRβ amino acid sequence
we generated nucleotide variants using a previously pub-
lished TCR recombination model [34] and compared the
resulting simulated nucleotide sequence variants between
donors. Then the total number of shared nucleotide se-
quences between twins in this simulation was compared
to the total number of shared nucleotide sequences be-
tween the twins in the data. The simulation was per-
formed 1000 times: in 979 cases out of 1000 the number
of nucleotide sequences shared between twins was less
than in the data, which gives a p-value=0.021. This re-
sult suggests, that at the least some of the nucleotide
sequences of YF-reactive clones may be shared prena-
tally between twin donors, because this extensive shar-
ing of nucleotide sequences cannot be explained by con-
vergent recombination and selection. On the contrary,
the number of shared nucleotide sequences between un-
related donors in the simulation was rarely less than in
the data (in 295 cases out of 1000), which means that the
nucleotide sequence sharing between unrelated individu-
als can easily be achieved by convergent recombination
alone (p-value=0.7).
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FIG. S1. Log10 cumulative frequency of published
YFV- and CMV-specific clonotypes in our CD8+
datasets. We found much higher relative abundance of
known YFV-reactive clonotypes on day 15 comparing to day
0 for each donor, however no such effect was found for known
CMV-reactive clonotypes.
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FIG. S2. Bimodality of YF-specific clone concentrations in the CD4+ and CD8+ compartments. For each
expanded clonotype from bulk PBMC we show relative fraction in CD4+ repertoire: fraction of 0 means that clonotype is
found exclusively in CD8+ repertoire, fraction of 1 means clonotype is found exclusively in CD4+ repertoire.
Locus S1 and S2 P1 and P2 Q1 and Q2
A 02:01:01/03:01:01 02:01:01/02:01:01 02:01:01/02:01:01
B 38:01:01/07:02:01 51:01:01/07:02:01 13:02:01/44:02:01
C 07:02:01/12:03:01 07:02:01/14:02:01 05:01:01/06:02:01
DQB1 06:03:01/06:02:01 03:01:01/04:02:01 02:02:01/06:03:01
DRB1 13:01:01/15:01:01 08:03:02/08:01:03 07:01:01/13:01:01
DRB3 01:01:02 - 01:01:02
DRB4 - - 01:03
TABLE S1. HLA-haplotypes of donors
13
0
0.25
0.5
0.75
1
P1 P2 Q1 Q2 S1 S2
Fr
ac
tio
n
CD4
CD8
0
0.25
0.5
0.75
1
P1 P2 Q1 Q2 S1 S2
Fr
ac
tio
n
CD4
CD8
A. B.
FIG. S3. Distribution of yellow fever reactive clono-
types between CD4+ and CD8+ subpopulations. A.
Relative fractions of activated clonotypes attributed to the
CD4+ and CD8+ compartments and B. relative fractions of
cells attributed to the CD4+ and CD8+ activated clonotypes
in each repertoire.
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FIG. S4. Scatterplot of clone frequencies in donor S1
on day 7 and day 15. Log10 of clone frequency (defined
as the ratio of the UMI for given clone and the sum of UMIs
in sample) on day 7 (x-axis) is plotted against log10 of clone
frequency on day 15. Pseudocounts of 1 UMI are used to show
0 on logarithmic scale. Red ticks on axes mark pseudocount
size, these clones have 0 concentration at the corresponding
timepoint. Red dots on the plot indicate clones significantly
expanded between day 0 and day 15.
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unvalidated and validated by functional tests. Un-
validated clones have significantly lower frequencies (t-test
p< 10−16)
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FIG. S6. Results of our analysis could be reproduced
using the edgeR differential gene expression analysis
software. A. Number of significantly expanded clonotypes
in comparison to day 0. B. The heatmap shows the number
of the same amino acid clonotypes between two sets of clones
significantly expanded from day 0 to day 15, divided by the
product of the sizes of these sets. C. and D. Dynamics of T-
cells in the CD4+ and CD8+ compartments. Total fractions
of CD4+ (C.) and CD8+ (D.) repertoires occupied by clono-
types significantly expanded from day 0 to day 15 is plotted
at different timepoints.
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S2 S1 P2 P1 Q2 Q1
CMV, 0 mism 0 0 0 0 0 0
YFV, 0 mism 6 3 1 2 4 3
CMV, 1 mism 0 0 1 0 2 0
YFV, 1 mism 9 24 9 12 21 5
CMV, 2 mism 8 5 3 5 10 2
YFV, 2 mism 29 27 11 24 37 19
TABLE S2. The number of YFV-reactive TCRβ sequences
found in this study that are similar to published TCRβ se-
quences specific for immunodominant YFV and CMV epi-
topes.
S2 S1 P2 P1 Q2 Q1
Fraction of public YFV-reactive clones 0.03 0.04 0.03 0.03 0.02 0.04
Cumulative freq. of public YFV-reactive clones 0.05 0.08 0.06 0.03 0.03 0.34
TABLE S3. Contribution of public clones to YFV response.
A TCRβ amino acid clonotype is considered public if it is
shared with at least one other donor in this study.
S2 S1 P2 P1 Q2 Q1
S2 970/955 5/20 0/3 0/4 2/9 1/3
S1 5/20 774/763 0/3 0/5 1/12 0/4
P2 0/3 0/3 800/792 1/18 0/2 0/0
P1 0/4 0/5 1/18 1151/1142 0/7 0/1
Q2 2/9 1/12 0/2 0/7 1537/1503 4/20
Q1 1/3 0/4 0/0 0/1 4/20 520/510
TABLE S4. The number of unique shared nucleotide/amino
acid sequences between YFV-reactive repertoires of our
donors. The diagonal shows the total number of unique
nucleotide/amino acid TCRβ sequences inside each YFV-
reactive repertoire.
